...
首页> 外文期刊>Cancer gene therapy >Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma
【24h】

Robust infectivity and replication of Delta-24 adenovirus induce cell death in human medulloblastoma

机译:Delta-24腺病毒的强大感染力和复制诱导人髓母细胞瘤的细胞死亡

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The diverse advanced treatment modalities currently available to children with medulloblastoma, including surgery and radiotherapy, are associated with deleterious side effects and often with an unfavorable prognosis. A mutant adenovirus, Delta-24, which has a 24-base pair deletion in the Rb-binding region of the E1A gene, demonstrates selective replication and oncolysis in various malignant phenotypes. Here we report the ability of Delta-24 to kill medulloblastoma cells. Flow cytometric analyses of cell receptors demonstrated expression of the coxsackie adenovirus receptor and RGD-related integrins in the assessed medulloblastoma cell lines. Infectivity assays using a replication-deficient adenovirus to transduce the green fluorescence protein gene showed that the Delta-24 adenovirus infects 99% of Daoy and 46% of D283 Med medulloblastoma cells at a multiplicity of infection (MOI) of 50. Within 4 days after infecting medulloblastoma cells with Delta-24, a noticeable cytopathic effect was produced. Delta-24 induced a total cytopathic effect in Daoy and D283 Med medulloblastoma cells after 6 and 8 days of infection, respectively. In the infected population of cells, cell death correlated with the accumulation of cells in the S phase. At 5 days post-infection with 2.5 MOIs of Delta-24 adenovirus, the percentage of Daoy medulloblastoma cells in the S phase increased to 71.95.5%, compared with control values of 20.51.4%. The release of viral progeny was quantified as being increased by two orders of magnitude, indicating efficient replication of Delta-24 in medulloblastoma cells. This is the first report of the ability of oncolytic adenoviruses to infect and kill medulloblastoma cells, the findings of which suggest the potential efficacy of Delta-24 as a therapy for human medulloblastoma tumors.
机译:目前可用于髓母细胞瘤儿童的多种先进治疗方式,包括手术和放疗,均与有害的副作用有关,并且往往预后不良。突变型腺病毒Delta-24在E1A基因的Rb结合区具有24个碱基对的缺失,它在各种恶性表型中表现出选择性复制和溶瘤作用。在这里,我们报告了Delta-24杀死髓母细胞瘤细胞的能力。细胞受体的流式细胞仪分析表明柯萨奇腺病毒受体和RGD相关整联蛋白在评估的成髓细胞瘤细胞系中的表达。使用复制缺陷型腺病毒转导绿色荧光蛋白基因的感染性分析表明,Delta-24腺病毒以50的感染复数(MOI)感染99%的Daoy和46%的D283 Med髓母细胞瘤细胞。感染后4天内用Delta-24感染髓母细胞瘤细胞,产生了明显的细胞病变作用。感染后第6天和第8天,Delta-24分别在Daoy和D283 Med髓母细胞瘤细胞中诱导了总的细胞病变作用。在感染的细胞群体中,细胞死亡与S期细胞的积累有关。在用2.5 MOI的Delta-24腺病毒感染后5天,S期中的Daoy髓母细胞瘤细胞百分比增加至71.95.5%,而对照值为20.51.4%。病毒后代的释放被定量为增加了两个数量级,表明Delta-24在髓母细胞瘤细胞中有效复制。这是溶瘤腺病毒感染和杀死髓母细胞瘤细胞能力的第一份报告,其发现表明,Delta-24作为治疗人髓母细胞瘤肿瘤的潜在功效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号